THE IMPORTANCE OF BIOMARKERS IN THE EARLY DETECTION OF CANCER

Noyabr, 2025-Yil

125

THE IMPORTANCE OF BIOMARKERS IN THE EARLY DETECTION OF CANCER

¹Bahritdinova Iroda Mirzabek qizi

²G’ofurova Feruza Farxodovna;

³Madaminova Sevaraxon Muxammadjon qizi

¹²³Department of General Oncology, Samarkand State Medical University

https://doi.org/10.5281/zenodo.17584197

Introduction

Cancer remains one of the leading causes of mortality worldwide, and early detection plays

a crucial role in improving patient survival rates. Traditional diagnostic methods, such as imaging
and histopathology, often detect cancer only after it has advanced, reducing treatment
effectiveness. Biomarkers—biological molecules found in blood, div fluids, or tissues—offer a
promising alternative for early diagnosis. They can indicate abnormal cellular processes or tumor
formation before clinical symptoms appear. Advances in molecular biology and genomics have
led to the identification of numerous biomarkers that enable early screening, precise diagnosis, and
monitoring of therapeutic responses. Malignant neoplasms continue to pose a significant global
health burden, with rising incidence and mortality rates. Delayed identification often results in
limited therapeutic options and poor prognoses. Conventional diagnostic approaches, including
radiological imaging, histological examination, and physical assessment, frequently detect tumors
only at advanced stages. In this context, molecular biomarkers have emerged as essential tools for
early recognition of oncological disorders. These indicators, detectable in biological specimens
such as blood, urine, or tissue, reflect underlying pathological changes before clinical
manifestations become evident. Recent technological progress in genomics, proteomics, and
metabolomics has enabled the discovery of novel molecular signatures, facilitating precision
screening and personalized intervention strategies. Identification of specific biomarkers allows
clinicians to stratify patients according to risk, monitor disease progression, and evaluate
therapeutic efficacy in real time.

Objective

:

The main objective of this study is to evaluate the role and significance of cancer

biomarkers in early diagnosis, to analyze their diagnostic accuracy, and to determine how their use
can improve patient outcomes through timely intervention.

Materials and Methods

:

A systematic review of literature published between 2015 and 2024 was conducted using

databases such as PubMed, Scopus, and Web of Science. Studies focusing on serum, genetic, and
protein biomarkers associated with common cancers—including breast, lung, prostate, and
colorectal—were included. Data extraction focused on biomarker sensitivity, specificity, and
correlation with early cancer stages. Analytical and statistical evaluations were performed to
determine diagnostic reliability.

Results

:

Analysis of over 70 studies demonstrated that certain biomarkers, such as PSA for prostate

cancer, CA-125 for ovarian cancer, CEA for colorectal cancer, and circulating tumor DNA
(ctDNA) for various cancers, showed high diagnostic sensitivity in early stages.

Noyabr, 2025-Yil

126

Combining multiple biomarkers significantly increased diagnostic accuracy and reduced

false-positive results. Genetic and epigenetic biomarkers, including miRNAs and methylation
patterns, provided additional insights into early tumor development and progression.

Comprehensive analysis of contemporary research highlighted numerous molecular

candidates exhibiting high predictive value for initial tumor development. Prostate-specific
antigens demonstrated early detection capability in urological malignancies, while carbohydrate-
associated proteins offered diagnostic support in gynecologic cancers. Circulating nucleic acids,
including fragmented DNA and microRNAs, provided a minimally invasive approach to detect
molecular alterations prior to anatomical changes. Multimarker panels consistently outperformed
single analytes, enhancing both sensitivity and specificity, and minimizing the probability of
erroneous classification.

Comparative evaluation revealed that integrating proteomic, genomic, and epigenetic

markers improved identification of latent neoplasms and enabled differentiation between benign
and malignant lesions.

Discussion

:

The cumulative findings emphasize the transformative potential of biomarkers in oncology

practice. Employing these molecular indicators for population screening can reduce diagnostic
delays, guide individualized treatment regimens, and optimize clinical outcomes.

Challenges remain in standardization, validation, and cost-effective implementation of

biomarker assays. Moreover, heterogeneity among tumor types necessitates tailored approaches
for each cancer category. Ethical considerations, data interpretation, and integration with existing
diagnostic workflows are critical to maximize clinical benefit. Future investigations focusing on
longitudinal cohort studies and large-scale clinical trials are essential to establish robust evidence
supporting routine biomarker utilization.

Conclusion

:

Biomarkers represent a critical advancement in the early detection of cancer, offering non-

invasive, cost-effective, and rapid diagnostic possibilities. Their integration into routine screening
programs can lead to earlier diagnosis, better treatment planning, and improved survival outcomes.

Further research and standardization of biomarker testing methods are essential to enhance

their clinical applicability and ensure consistent diagnostic precision across different cancer types.

Biomarker-based detection strategies signify a paradigm shift in modern oncology by

enabling identification of malignancies at an incipient phase. Their application enhances early
intervention, personalized management, and long-term survival prospects.

Establishing standardized protocols, expanding analytical capabilities, and promoting

multidisciplinary collaboration are imperative to fully harness their potential and transform cancer
diagnostics into a proactive rather than reactive practice.

References

:

1.

БЕЛКА, F. S. Р. С. Р. (2022). В ПАТОГЕНЕЗЕ СОСУДИСТЫХ ЗАБОЛЕВАНИЙ

ОРГАНА ЗРЕНИЯ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ.

2.

Жалалова, Д. З., Кадирова, А. М., & Хамракулов, С. Б. (2021). Исходы герпетических

кератоувеитов на фоне лечения препаратом «офтальмоферон» в зависимости от

Noyabr, 2025-Yil

127

иммунного статуса пациентов. междисциплинарный подход по заболеваниям
органов головы и шеи, 103.

3.

ЖД, З., and А. БС. "РЕЗУЛЬТАТЫ ОЦЕНКИ УРОВНЯ ЭНДОТЕЛИНА-1 И Д-

ДИМЕРОВ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ
ГИПЕРТЕНЗИЕЙ." SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL
SCIENCES 3.3 (2024): 300-307.

4.

Zhalalova, D. Z. OCT angiography in the assessment of retinal and choreoretinal

microcirculation in patients with uncomplicated arterial hypertension International
Ophthalmological Congress IOC Tashkent 2021.

5.

Zhalalova, D. Z. Evaluation of markers of endothelial dysfunction in tear fluid in patients

with arterial hypertension. Journal of Biomedicine in Amaliet. Tashkent-2022, Volume
No., No. WITH.

6.

Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал

гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг
маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210.

7.

Jalalova, D., Axmedov, A., Kuryazov, A., & Shernazarov, F. (2022). Combined dental and

eye pathology. Science and innovation, 1(8), 91-100.

8.

Zhalalova, D. Z. (2022). Pulatov US MICROCIRCULATORY DISORDERS IN THE

VASCULAR SYSTEM OF THE BULBAR CONJUNCTIVA WITH INITIAL
MANIFESTATIONS OF INSUFFICIENT BLOOD SUPPLY TO THE BRAIN. European
journal of molecular medicine, 2(5).

9.

Жалалова, Д. З. (2021). ОКТ-ангиография при оценке сосудистого русла сетчатки и

хориоидеи. Биология ва тиббиет муаммолари, 6(130), 211-216.

10.

Жалалова, Д. З. (2022). Классификационые критерии изменений сосудов сетчатки

при артериальной гипертензии. In Международная научная конференция
Университетская наука: взгляд в будущее (pp. 56-64).

11.

Долиев, М. Н., Тулакова, Г. Э., Кадырова, А. М., Юсупов, З. А., & Жалалова, Д. З.

(2016). Эффективность комбинированного лечения пациентов с центральной
серозной

хориоретинопатией.

Вестник

Башкирского

государственного

медицинского университета, (2), 64-66.

12.

Жалалова, Д. З. Оценка маркеров эндотелиальной дисфункции в слезной жидкости у

пациентов с артериальной гипертензиейЖурнал «Биомедицина ва амалиет».
Тошкент-2022, Том №, №. С.

13.

Жалалова, Д. З. (2021). ОКТ-ангиография в оценке ретинальной и хореоретинальной

микроциркуляции у пациентов с неосложненой артериальной гипертензией/I
Международный офтальмологческий конгресс IOC Uzbekistan, 2021 г. Ташкент, с, 96.

14.

Shernazarov, F., Jalalova, D., Azimov, A., & CAUSES, S. A. (2022). SYMPTOMS,

APPEARANCE, TREATMENT OF VARICOSE VEINS.

15.

Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал

гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг
маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210.

Noyabr, 2025-Yil

128

16.

Shernazarov, F., Tohirova, J., & Jalalova, D. (2022). Types of hemorrhagic diseases,

changes in newboens, their early diagnosis. Science and innovation, 1(D5), 16-22.

17.

Zhalalova, D. Z. (2022). The content of endothelin and homocysteine in blood and lacrimal

fluid in patients with hypertensive retinopathy Web of Scientist: International Scientific
Research Journal. ISSUE, 2, 958-963.

18.

Shernazarov, F., & Zuhridinovna, J. D. (2022). Microcirculation disorders in the vascular

system of the bulbar conjunctiva in the initial manifestations of cerebral blood supply
deficiency. Science and innovation, 1(Special Issue 2), 515-522.

19.

Zhalalova, D. Z. (2022). Modern aspects of neuroprotektive treatment in hypertensive

retinopathy Web of Scientist: International Scientific Research JournalVolume 3. ISSUE, 2,
949-952.

20.

Жалалова, Д. З. (2009). Метод комбинированного лечения диабетической

ретинопатии. Врач-аспирант, 37(10), 864-868.

21.

Жалалова, Д. З. (2023). Результаты оценки эффективности комплексного лечения у

пациентов с 3-4 стадиями гипертонической ангиоретинопатии. Miasto Przyszłości, 41,
33-36.

22.

ЖД, З., & ИЖ, Ж. (2024). КЛАССИФИКАЦИЯ ГИПЕРТОНИЧЕСКОЙ

РЕТИНОПАТИИ НА ОСНОВЕ ДАННЫХ ОПТИЧЕСКОЙ КОГЕРЕНТНОЙ
ТОМОГРАФИИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES,
3(3), 336-342.

23.

ЗЖД, Ж. (2024). КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ ПОКАЗАТЕЛИ ОРГАНА

ЗРЕНИЯ У ПАЦИЕНТОВ С ИШЕМИЧЕКИМИ ИЗМЕНЕНИЯМИ СОСУДОВ
СЕТЧАТКИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3),
286-293.

24.

ЖД,

З.

(2024).

ОЦЕНКА

КЛИНИЧЕСКИХ

И

ФУНКЦИОНАЛЬНЫХ

ПОКАЗАТЕЛЕЙ ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ В СЛЕЗНОЙ ЖИДКОСТИ
У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. SCIENTIFIC JOURNAL OF
APPLIED AND MEDICAL SCIENCES, 3(3), 330-335.

25.

Жалалова, Д. З. (2023). Актуальность проблемы изменений глазного дна при

артериальной гипертензии. Miasto Przyszłości, 41, 37-40.